MSL Society Announces Inaugural Global Conference and Gala

February 7, 2013 · Leave a comment

For Immediate Release

February 7, 2013 (Chapel Hill, NC) The Medical Science Liaison Society (MSL Society) is planning its first global conference and gala for April 2013.

The event will take place at Philadelphia’s Hyatt at the Broadview on South Broad Street, from April 1-3.  The 2013 MSL Society Conference and Gala is the first event of its kind, a tangible extension of the non-profit organization’s mission to bring together global medical affairs professionals for education and networking in an effort to support the profession.

Attendees will include Medical Affairs and MSL Leadership, as well as other professionals focusing on key topic including KOL access, HEOR, clinical trials, clinical investigation, key opinion leader relationship management, and medical communications.  The emerging roster of speakers includes luminaries from the world of medical affairs, including Dr. Stewart Rosen, Vice President of Medical Affairs at Quintiles, Dr. Robert Ang, Vice President of Medical Affairs at Cadence Pharmaceuticals, and Dr. Elizabeth Kupferer, Director of Medical Affairs at Sequenom.  

Highlights of the three-day event include a welcome reception on day one, followed by a full day of education and networking, the gala dinner to culminate day two, and a final round of education and networking on day three.

“We’ve planned our first live conference with the needs ... read more »

TAGS:                                                         

Thought Leader Select’s Deep Profiling Identifies New KOLs, Rising Stars for Pharmaceutical Development

April 20, 2010 · Leave a comment

At Thought Leader Select, we employ a proprietary research methodology to identify key opinion leaders (KOLs) for pharmaceutical and biotechnology companies.  This methodology, known as deep profiling, enables biopharmaceutical firms to optimize teams of KOLs for different deployment areas throughout the development of new medicines and during the life cycles of their brands.

At the core of our methodology is a belief in the uniqueness of each key opinion leader, whether he or she is a physician, physician assistant, nurse practitioner, pharmacist, veterinarian, or other leader in the health care sector.  According to Dr. Max Noureddine, Thought Leader Select’s chief scientific officer, we define key opinion leaders as “the people who leave a footprint in the field.”

“KOLs are the people who make noticeable contributions to the medical field, by advancing science and blazing new paths forward for other scientists in the field,” said Noureddine.  “Their achievements in basic and clinical research, clinical investigation, and their treatment of patients have a remarkable impact on others in the field. Quite simply, key opinion leaders are the change agents within the field—they cause fundamental changes in how we look at different diseases and how we can possibly treat them, and others follow their work accordingly.”

KOLs change the course of pharmaceutical discovery and development ... read more »

TAGS:                                     

Italy's D3 Unites Pharmaceutical Industry, Academia for Public Health

April 13, 2010 · 1 comment

A report in yesterday’s Pharma Letter illustrates how critical partnerships between the pharmaceutical industry and academia can be beneficial for patients, medical professionals and the pharmaceutical industry alike. The Italian Institute of Technology’s Drug Discovery and Development Unit (D3) “brings together scientists with experience in industry and academia to discover new drugs in pain, inflammation and dementia.” Having already received considerable funding from the Italian government, D3 is interested in partnering with external collaborators to further projects.

Through its in-depth key opinion leader (KOL) identification and profiling, Thought Leader Select sees how many similar partnerships around the globe are successful in creating innovative therapies and furthering scientific work. We look forward to the advancements that D3 is sure to bring. As partnerships between the industry and leading academic centers of excellence continue to form, we expect today’s breakthrough compounds to become tomorrow’s key medicines for global public health much more quickly.

Institutes like the D3 in Italy will illustrate, on an even greater level, the synergies that inevitably develop when the pharmaceutical industry teams up with the right key opinion leaders for clinical investigation, advisory boards, editorial boards, and other key areas of deployment.

Read the full article here.


TAGS: